Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) FCF Margin (2016 - 2025)

Historic FCF Margin for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to 430.85%.

  • Ocular Therapeutix's FCF Margin fell 1988500.0% to 430.85% in Q4 2025 from the same period last year, while for Dec 2025 it was 417.5%, marking a year-over-year decrease of 2041200.0%. This contributed to the annual value of 417.5% for FY2025, which is 2041300.0% down from last year.
  • Per Ocular Therapeutix's latest filing, its FCF Margin stood at 430.85% for Q4 2025, which was down 1988500.0% from 389.98% recorded in Q3 2025.
  • Ocular Therapeutix's 5-year FCF Margin high stood at 52.99% for Q3 2023, and its period low was 435.63% during Q1 2025.
  • For the 5-year period, Ocular Therapeutix's FCF Margin averaged around 209.82%, with its median value being 163.53% (2023).
  • As far as peak fluctuations go, Ocular Therapeutix's FCF Margin soared by 7787300bps in 2021, and later plummeted by -2651300bps in 2025.
  • Ocular Therapeutix's FCF Margin (Quarter) stood at 128.24% in 2021, then decreased by -6bps to 135.76% in 2022, then fell by -14bps to 154.81% in 2023, then crashed by -50bps to 232.0% in 2024, then plummeted by -86bps to 430.85% in 2025.
  • Its last three reported values are 430.85% in Q4 2025, 389.98% for Q3 2025, and 419.67% during Q2 2025.